Share Twitter LinkedIn Facebook Email Earn CME: https://www.naccme.com/program/19-cpc-101-7 This webcast features a presentation by Dr. Gary H. Lyman that examines the potential benefits of incorporating biosimilars into oncology clinical pathways. © 2019 NACCME, an HMP Company
Understanding and Managing BPDCN: Insights from Priyanka Meta’s Conference Presentation Other 2 Mins Read
Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission [ASH 2023] Other 1 Min Read